Depression research has entered a transformative period. The 2019 approval of esketamine (Spravato) for treatment-resistant depression validated a new mechanism after decades of incremental SSRI/SNRI development. Psilocybin, MDMA-assisted therapy, novel rapid-acting antidepressants, and refined neuromodulation approaches are all in active development. For patients with depression, particularly those with treatment-resistant disease, clinical trials for depression can offer access to investigational therapies. This guide covers how to find depression trials, active research areas, eligibility considerations, and resources.
Categories of depression trials
Active depression trials in 2026 include:
Psychedelic-assisted therapy: Psilocybin trials for treatment-resistant depression continue toward potential FDA approval. MDMA-assisted therapy faced setbacks in 2024 but trials continue. Various other psychedelics in earlier development.
Ketamine and esketamine extensions: Trials of esketamine in expanded indications, novel formulations, and combinations. Ketamine analogs targeting NMDA receptors with potentially better safety profiles.
Rapid-acting antidepressants: Drugs targeting GABA-A receptors (zuranolone is approved for postpartum depression; broader trials), AMPA receptors, and other rapid-onset mechanisms.
Novel mechanisms: Anti-inflammatory approaches, kappa opioid receptor antagonists, glutamate modulators, neurotrophic factor approaches.
Neuromodulation: Refined transcranial magnetic stimulation (TMS) protocols, deep brain stimulation for treatment-resistant depression, theta burst stimulation.
Digital therapeutics: App-based cognitive-behavioral therapy programs, sometimes combined with medication.
Where to find depression trials
Resources:
- ClinicalTrials.gov
- National Alliance on Mental Illness (NAMI)
- Anxiety and Depression Association of America (ADAA)
- Major academic psychiatry programs
- NIMH research initiatives
Treatment-resistant depression trials
Treatment-resistant depression (TRD) — typically defined as failure to respond to two or more adequate trials of antidepressants — is the focus of much depression research. Patients with TRD often have the strongest case for trial participation since standard options have been exhausted.
TRD-specific trials include esketamine extensions, psilocybin therapy, novel rapid-acting agents, and neuromodulation approaches. NIMH funds extensive TRD research.
Typical eligibility for depression trials
Common inclusion criteria:
- Major depressive disorder diagnosis meeting DSM-5 criteria
- Specific severity (often HAM-D or PHQ-9 score in range)
- For TRD trials: documented failure of multiple adequate medication trials
- Stable concurrent psychiatric medications (varies by trial)
- Capacity to provide informed consent
Common exclusion criteria:
- Active suicidality (acute suicide risk; chronic suicidality may be acceptable)
- Bipolar disorder (separate trials)
- Active psychosis
- Severe substance use disorder
- Specific medical conditions
- Pregnancy
What participation involves
Depression trials typically involve:
- Baseline psychiatric evaluation and depression scale assessments
- Treatment with experimental therapy (oral medication, IV/intranasal administration, neuromodulation, psychedelic-assisted therapy depending on trial)
- Regular study visits with depression scale assessments
- Safety monitoring including suicidality screening
- Quality of life and functional assessments
- Long-term follow-up
Psychedelic trial considerations
Psychedelic-assisted therapy trials have specific structure:
- Extensive screening and preparation sessions
- Dosing sessions (typically 1-3 sessions over weeks/months) with therapist support
- Integration sessions after dosing
- Long-term follow-up
The therapeutic context is integral to the intervention — these trials test “psychedelic-assisted therapy” rather than psychedelics alone.
Frequently Asked Questions
Are psychedelic trials open to anyone with depression?
Most are TRD-focused, requiring documented failure of multiple antidepressants. Some have expanded eligibility. Specific exclusions for cardiac conditions, psychosis history, and certain medications.
What is esketamine?
The S-enantiomer of ketamine, FDA-approved as Spravato for treatment-resistant depression. Administered intranasally in supervised settings. Trials test esketamine in expanded indications.
Are TMS trials available?
Yes. TMS protocols continue to evolve, with newer accelerated protocols (SAINT, etc.) showing rapid antidepressant effects. Trials test optimization of TMS approaches.
Can I be in a depression trial if I’m on antidepressants?
Depends on the trial. Some require medication washout; others test add-on therapies on stable medications.
What if I have suicidal thoughts?
Active suicidality typically excludes patients from outpatient trials. Some specialized trials enroll patients with suicidality with intensive monitoring (Brightside Health’s Crisis Care is one example, though not a clinical trial).
The bottom line on depression trials
Depression research is in a transformative period with psychedelic-assisted therapy, rapid-acting agents, and novel mechanisms challenging traditional SSRI/SNRI dominance. For treatment-resistant depression, trials offer meaningful options. Major academic psychiatry programs and NIMH-funded research networks provide trial access. Discuss with your psychiatrist as part of treatment planning.